PTK787/ZK 222584, a small molecule tyrosine kinase receptor inhibitor of vascular endothelial growth factor (VEGF), has modest activity in myelofibrosis with myeloid metaplasia

Francis J. Giles; Alan F. List; Michael Carroll; Jorge E. Cortes; Joyce Valickas; Bee Lian Chen; Eric Masson; Christian Jacques; Dirk Laurent; Maher Albitar; Eric J. Feldman; Gail J. Roboz

doi:10.1016/j.leukres.2006.12.001

PTK787/ZK 222584, a small molecule tyrosine kinase receptor inhibitor of vascular endothelial growth factor (VEGF), has modest activity in myelofibrosis with myeloid metaplasia

Francis J. Giles^*, Alan F. List, Michael Carroll, Jorge E. Cortes, Joyce Valickas, Bee Lian Chen, Eric Masson, Christian Jacques, Dirk Laurent, Maher Albitar, Eric J. Feldman, Gail J. Roboz

^*Corresponding author for this work

Medicine, Hematology Oncology Division

Research output: Contribution to journal › Article › peer-review

22 Scopus citations

Abstract

Angiogenesis is part of the pathophysiology of myelofibrosis with myeloid metaplasia (MMM). PTK787/ZK 222584 (PTK/ZK) is a novel inhibitor of vascular endothelial growth factor receptors. Twenty-nine patients with MMM received a continuous dosing schedule of PTK/ZK doses of 500 or 750 mg twice daily (BID). Transient potentially PTK/ZK related mild nausea, vomiting, dizziness, fatigue, thrombocytopenia, or anorexia occurred in 15% of patients. Dose limiting toxicities of dyspepsia, proteinurea, and/or mucositis were observed in patients treated with 750 mg BID. One (3%) and five (17%) patients achieved complete remission and clinical improvement, respectively. PTK/ZK has modest activity in patients with MMM.

Original language	English (US)
Pages (from-to)	891-897
Number of pages	7
Journal	Leukemia Research
Volume	31
Issue number	7
DOIs	https://doi.org/10.1016/j.leukres.2006.12.001
State	Published - Jul 2007

Keywords

Angiogenesis
Myelofibrosis
Tyrosine kinase inhibitor
VEGF

ASJC Scopus subject areas

Hematology
Oncology
Cancer Research

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.leukres.2006.12.001

Cite this

Giles, F. J., List, A. F., Carroll, M., Cortes, J. E., Valickas, J., Chen, B. L., Masson, E., Jacques, C., Laurent, D., Albitar, M., Feldman, E. J., & Roboz, G. J. (2007). PTK787/ZK 222584, a small molecule tyrosine kinase receptor inhibitor of vascular endothelial growth factor (VEGF), has modest activity in myelofibrosis with myeloid metaplasia. Leukemia Research, 31(7), 891-897. https://doi.org/10.1016/j.leukres.2006.12.001

@article{310c49005cd245f886e18a6f6cceb12a,

title = "PTK787/ZK 222584, a small molecule tyrosine kinase receptor inhibitor of vascular endothelial growth factor (VEGF), has modest activity in myelofibrosis with myeloid metaplasia",

abstract = "Angiogenesis is part of the pathophysiology of myelofibrosis with myeloid metaplasia (MMM). PTK787/ZK 222584 (PTK/ZK) is a novel inhibitor of vascular endothelial growth factor receptors. Twenty-nine patients with MMM received a continuous dosing schedule of PTK/ZK doses of 500 or 750 mg twice daily (BID). Transient potentially PTK/ZK related mild nausea, vomiting, dizziness, fatigue, thrombocytopenia, or anorexia occurred in 15% of patients. Dose limiting toxicities of dyspepsia, proteinurea, and/or mucositis were observed in patients treated with 750 mg BID. One (3%) and five (17%) patients achieved complete remission and clinical improvement, respectively. PTK/ZK has modest activity in patients with MMM.",

keywords = "Angiogenesis, Myelofibrosis, Tyrosine kinase inhibitor, VEGF",

author = "Giles, {Francis J.} and List, {Alan F.} and Michael Carroll and Cortes, {Jorge E.} and Joyce Valickas and Chen, {Bee Lian} and Eric Masson and Christian Jacques and Dirk Laurent and Maher Albitar and Feldman, {Eric J.} and Roboz, {Gail J.}",

year = "2007",

month = jul,

doi = "10.1016/j.leukres.2006.12.001",

language = "English (US)",

volume = "31",

pages = "891--897",

journal = "Leukemia Research",

issn = "0145-2126",

publisher = "Elsevier Ltd",

number = "7",

}

Giles, FJ, List, AF, Carroll, M, Cortes, JE, Valickas, J, Chen, BL, Masson, E, Jacques, C, Laurent, D, Albitar, M, Feldman, EJ & Roboz, GJ 2007, 'PTK787/ZK 222584, a small molecule tyrosine kinase receptor inhibitor of vascular endothelial growth factor (VEGF), has modest activity in myelofibrosis with myeloid metaplasia', Leukemia Research, vol. 31, no. 7, pp. 891-897. https://doi.org/10.1016/j.leukres.2006.12.001

TY - JOUR

T1 - PTK787/ZK 222584, a small molecule tyrosine kinase receptor inhibitor of vascular endothelial growth factor (VEGF), has modest activity in myelofibrosis with myeloid metaplasia

AU - Giles, Francis J.

AU - List, Alan F.

AU - Carroll, Michael

AU - Cortes, Jorge E.

AU - Valickas, Joyce

AU - Chen, Bee Lian

AU - Masson, Eric

AU - Jacques, Christian

AU - Laurent, Dirk

AU - Albitar, Maher

AU - Feldman, Eric J.

AU - Roboz, Gail J.

PY - 2007/7

Y1 - 2007/7

N2 - Angiogenesis is part of the pathophysiology of myelofibrosis with myeloid metaplasia (MMM). PTK787/ZK 222584 (PTK/ZK) is a novel inhibitor of vascular endothelial growth factor receptors. Twenty-nine patients with MMM received a continuous dosing schedule of PTK/ZK doses of 500 or 750 mg twice daily (BID). Transient potentially PTK/ZK related mild nausea, vomiting, dizziness, fatigue, thrombocytopenia, or anorexia occurred in 15% of patients. Dose limiting toxicities of dyspepsia, proteinurea, and/or mucositis were observed in patients treated with 750 mg BID. One (3%) and five (17%) patients achieved complete remission and clinical improvement, respectively. PTK/ZK has modest activity in patients with MMM.

AB - Angiogenesis is part of the pathophysiology of myelofibrosis with myeloid metaplasia (MMM). PTK787/ZK 222584 (PTK/ZK) is a novel inhibitor of vascular endothelial growth factor receptors. Twenty-nine patients with MMM received a continuous dosing schedule of PTK/ZK doses of 500 or 750 mg twice daily (BID). Transient potentially PTK/ZK related mild nausea, vomiting, dizziness, fatigue, thrombocytopenia, or anorexia occurred in 15% of patients. Dose limiting toxicities of dyspepsia, proteinurea, and/or mucositis were observed in patients treated with 750 mg BID. One (3%) and five (17%) patients achieved complete remission and clinical improvement, respectively. PTK/ZK has modest activity in patients with MMM.

KW - Angiogenesis

KW - Myelofibrosis

KW - Tyrosine kinase inhibitor

KW - VEGF

UR - http://www.scopus.com/inward/record.url?scp=34249826968&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34249826968&partnerID=8YFLogxK

U2 - 10.1016/j.leukres.2006.12.001

DO - 10.1016/j.leukres.2006.12.001

M3 - Article

C2 - 17560285

AN - SCOPUS:34249826968

SN - 0145-2126

VL - 31

SP - 891

EP - 897

JO - Leukemia Research

JF - Leukemia Research

IS - 7

ER -

PTK787/ZK 222584, a small molecule tyrosine kinase receptor inhibitor of vascular endothelial growth factor (VEGF), has modest activity in myelofibrosis with myeloid metaplasia

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this